Neoadjuvant chemotherapy for ovarian cancer: pro versus con

References

• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56(2):106–130
   PubMed Web of Science ®Google Scholar
• Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. J Epidemiol Biostat 2001;6(1):107–138
   PubMedGoogle Scholar
• NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Develop-ment Panel on Ovarian Cancer. JAMA 1995;273(6): 491–497
   Google Scholar
• Meigs JV. Tumors of the female pelvic organs. New York: Macmillan; 1934
   Google Scholar
• Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101–104
   PubMedGoogle Scholar
• Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus in-travenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335(26): 1950–1955
   PubMed Web of Science ®Google Scholar
• Le T, Krepart GV, Lotocki RJ, et al. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma? Gynecol Oncol 1997;67 ( 2 ):208–214
   Google Scholar
• Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998;69(2):103–108
   Google Scholar
• Frei E, 3rd. Clinical cancer research: an embattled species. Cancer 1982;50(10):1979–1992
   Google Scholar
• Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335(7):462–467
   PubMed Web of Science ®Google Scholar
• Weese JL, Harbison SP, Stiller GD, et al. Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): improved treatment for gastric adenocarcinoma. Surgery 2000;128 (4 ):564–571
   Google Scholar
• Berek JS. Interval debulking of ovarian cancer-an interim measure. N Engl J Med 1995;332(10):675–677
   Google Scholar
• Hacker NF, Berek JS, Lagasse LD, et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61(4):413–420
   PubMed Web of Science ®Google Scholar
• Hoskins WJ, Bundy BN, Thigpen JT, et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47(2):159–166
   PubMed Web of Science ®Google Scholar
• Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 2000;78 (3 Pt 0:269–274
   Google Scholar
• Hunter RW, Alexander ND, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992;166(2):504–511
   Google Scholar
• Berchuck A, Iversen ES, Lancaster JM, et al. Prediction of optimal versus suboptimal cytoreduction of advancedstage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 2004;190(4):910�925
   Google Scholar
• Naik R, Nordin A, Cross PA, et al. Complete cytoreduction: is epithelial ovarian cancer confined to the pelvis biologically different from bulky abdominal disease? Gynecol Oncol 2000;78(2):176�180
   Google Scholar
• Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63(11�12):1727�1733
   Google Scholar
• Allen DG, Heintz AP, Touw FW. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol 1995;16(5):349�356
   Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-
   Google Scholar
• Lawton FG, Redman CW, Luesley DM, et al. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial
   Google Scholar
• Schwartz PE, Rutherford TJ, Chambers JT, et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 1999;72(1):93–99
   Google Scholar
• Ansquer Y, Leblanc E, Clough K, et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 2001;91(12):2329� 2334
   Google Scholar
• Hegazy MA, El-Shafei MA, Setit AE, et al. Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. World J Surg Oncol 2005;3(1):57
   Google Scholar
• Blythe JG, Wahl TP. Debulking surgery: does it increase the quality of survival? Gynecol Oncol 1982;14(3):396� 408
   Google Scholar
• Chan YM, Ng TY, Ngan HY, et al. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 2003;88(1):9�16
   Google Scholar
• Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170(4):974�979; discussion 979�980
   Google Scholar
• Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced
   Google Scholar
• Hoskins WJ. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol 1994;55(3 Pt 2)
   Google Scholar
• Chi DS, Liao JB, Leon LF, et al. Identification of prognostic factors in advanced epithelial ovarian carci-noma. Gynecol Oncol 2001;82(3):532–537
   PubMed Web of Science ®Google Scholar
• Chi DS, Venkatraman ES, Masson V, et al. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000;77(2):227–231
   PubMed Web of Science ®Google Scholar
• Kuhn W, Rutke S, Spathe K, et al. Neoadjuvant chemo-therapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carci-noma. Cancer 2001;92(10):2585–2591
   Google Scholar
• Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993;11(1):166–172
   Google Scholar
• Meyer JI, Kennedy AW, Friedman R, et al. Ovarian carcinoma: value of CT in predicting success of debul-king surgery. AJR Am J Roentgenol 1995;165(4): 875–878
   Google Scholar
• Bristow RE, Duska LR, Lambrou NC, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000;89(7):1532–1540
   Google Scholar
• Qayyum A, Coakley FV, Westphalen AC, et al. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. Gynecol Oncol 2005;96(2):301–306
   Google Scholar
• Vergote I, De Weyer I, Tjalma W, et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998;71(3):431–436
   PubMed Web of Science ®Google Scholar
• van Dam PA, DeCloedt J, Tjalma WA, et al. Trocar implantation metastasis after laparoscopy in patients with advanced ovarian cancer: can the risk be reduced? Am J Obstet Gynecol 1999;181(3):536–541
   Google Scholar
• Mazzeo F, Berliere M, Kerger J, et al. Neoadjuvant chemotherapy followed by surgery and adjuvant che-motherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol 2003; 90(1):163–169
   Google Scholar
• Loizzi V, Cormio G, Resta L, et al. Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study. Int J Gynecol Cancer 2005;15(2):217–223
   Google Scholar
• van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gyne-cological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332(10):629–634
   Google Scholar
• Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004;351(24):2489–2497
   PubMed Web of Science ®Google Scholar
• Piver MS, Baker T. The potential for optimal (less than or equal to 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: a prospective study. Gynecol Oncol 1986;24(1):1–8
   Google Scholar
• Bristow RE, Montz FJ. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol Oncol 2001;83(1):39–48
   Google Scholar
• Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 2004;94(3 ):650–654
   PubMed Web of Science ®Google Scholar
• Cliby W, Dowdy S, Feitoza SS, et al. Diaphragm resection for ovarian cancer: technique and short-term complica-tions. Gynecol Oncol 2004;94(3):655–660
   Google Scholar
• Surwit E, Childers J. Cytoreductive surgery in advanced ovarian cancer with or without neoadjuvant chemother-apy. Abstracts presented for the 30th Annual Meeting of the Society of Gynecologic Oncologists. Gynecol Oncol 1999;72:468
   Google Scholar
• Vrscaj MU, Rakar S. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study. Eur J Gynaecol Oncol 2002;23(5): 405–410
   Google Scholar
• McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophos-phamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334(1):1–6
   PubMed Web of Science ®Google Scholar
• Le T, Faught W, Hopkins L, et al. Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer. Int J Gynecol Cancer 2005;15:770–775
   PubMedGoogle Scholar
• Eisenkop SM, Spirtos NM, Friedman RL, et al. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 2003;90(2):390–396
   PubMed Web of Science ®Google Scholar
• Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006 [May 19; Epub ahead of print]
   Google Scholar
• Curtin JP, Malik R, Venkatraman ES, et al. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 1997;64(1):9–12
   PubMed Web of Science ®Google Scholar
• Bristow RE, Montz FJ, Lagasse LD, et al. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999;72(3):278–287
   PubMed Web of Science ®Google Scholar